Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53
β Scribed by Stuart D. Tyner; Jene Choi; Rodolfo Laucirica; Richard J. Ford; Lawrence A. Donehower
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 832 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0899-1987
No coin nor oath required. For personal study only.
β¦ Synopsis
A number of transgenic animal model systems have addressed the mechanistic role of p53 loss in tumor progression. However, many of these tumor models have analyzed p53 function in the context of other transgenes expressing activated oncogenes or defective tumor suppressor genes generated by gene targeting. To examine the role of p53 loss independent of other exogenous oncogenic influences, we analyzed some of the biological aspects of tumor formation and progression in p53-knockout mice containing a null germline p53 allele. We analyzed tumors from p53-/-, p53+/-, and p53+/+ littermates. Some of the p53+/tumors had lost the remaining p53 allele (p53+/-loss of heterozygosity), whereas others retained the allele (p53+/-). In this report, we show that loss or absence of p53 conferred a tumor growth advantage by increasing the rate of cellular proliferation in a p53 dosage-dependent manner. The apoptotic levels in tumor tissue were found to be modest and not significantly dependent on p53 status. These results contrast with those from some other p53-deficient tumor models, in which p53 loss was associated with more rapid tumor progression through abrogated apoptosis. Finally, as p53 has been shown to regulate certain angiogenic factors, we examined the levels of angiogenesis in p53-containing and p53-deficient tumors. We found no p53dependent differences in the levels of tumor angiogenesis measured by intratumoral microvessel density.
π SIMILAR VOLUMES
## Abstract Wildβtype (WT) sequence p53 peptides are attractive candidates for broadly applicable cancer vaccines. The aim of this study was to evaluate the potential of a WT p53βbased immunotherapeutic approach for patients with hepatocellular carcinoma (HCC). Circulating CD8^+^ T cells specific f
Recent results suggest that p53 inactivation is required for cervical-carcinoma development. The mdm-2 oncogene, which forms an auto-regulatory feedback loop with the normal p53 protein, has been found amplified in human carcinomas, thus abolishing the anti-proliferative function of p53. To investig